China Wearable Technology: Smartwatches, Hearables, and Health Monitors

Yes, several Chinese smartwatches have achieved medical-grade blood pressure monitoring accuracy: Huawei Watch D2 is the first smartwatch approved by China's NMPA (National Medical Products Administration) for clinical blood pressure measurement, using a micro airbag system that inflates against the wrist similar to a traditional cuff; validation studies showed mean absolute difference of less than 5mmHg compared to professional medical devices, meeting clinical standards; the device is classified as a Class II medical device in China and can be used for blood pressure management by hypertensive patients; however, limitations include measurement requires the user to remain still with the arm at heart level for approximately 30 seconds, ambient temperature can affect accuracy, and it is not recommended as a replacement for regular medical checkups; Huawei Watch GT 5 series uses optical blood pressure estimation (without airbag) which is less accurate but more convenient; and other Chinese brands including Honor (Watch 5 Pro) and Amazfit are developing similar features. For consumers with hypertension, the Huawei Watch D2 represents a genuine medical tool, but should be used as a supplement to rather than a replacement for traditional medical monitoring.

China represents approximately 35% of the global wearable technology market by revenue and 40% by unit shipments: by volume, China ships approximately 400 million wearable devices annually, more than any other single country, including approximately 80 million smartwatches, 150 million TWS earbuds, 100 million fitness bands, and 70 million other wearables; by revenue, China's 120 billion RMB (approximately 16 billion USD) wearable market trails only the US (approximately 25 billion USD) globally; Chinese brands dominate globally in fitness bands with over 90% combined market share through Xiaomi and Huawei, and in TWS earbuds with 45% of global shipments through Huawei, Xiaomi, QCY, Edifier, and Oppo; however, Apple Watch still leads globally in smartwatch revenue despite holding only approximately 20% of the China smartwatch market; China leads in wearable health innovation, particularly in blood pressure monitoring, continuous glucose monitoring patches, and sleep apnea detection on wearables; and China's competitive advantage lies in offering flagship-level features at 1/3 to 1/5 the price of Western competitors, driven by efficient supply chain integration and aggressive pricing strategies. The Chinese wearable market is expected to grow 15% annually through 2028, outpacing the global average of 10%.